


GCIG Website





Enhancing the Global Impact of Clinical Trials in Gynecologic Cancer

Promote international cooperation

Promote clinical research

Perform studies in rare tumors

Stimulate evidence-based medicine

Support educational activities

Mission Statement:

The Gynecological Cancer InterGroup aims to promote and facilitate high quality clinical trials in order to improve outcomes for women with gynecological cancer.

Vision Statement:

Improving quality and duration of life for women with gynecologic cancers will be accomplished through a focused common purpose, shared expertise, and mutual respect among members, and with recognition and accommodation of cultural, geographic, and clinical diversities amongst and between members and patients.

Current Chair
William Small Jr.

Immediate Past Chair
Eric Pujade-Lauraine

Chair Elect:
Andres Poveda



Harmonization

Calendar

Meetings

GCIG Clinical
Trials

Bibliography

Clinical Q & A

Roster

Harmonization

- ▶ Harmonization page– there is a private page with a username and password that currently is not being used (harmonization committee)
- ▶
- ▶ Verification the CURRENT versions are on the final open page (Harmonization)

Event listing (under calendar)

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Search

Home Membership **Calendar** Library Harmonization Committee Meetings Announcements

CA 125 Response Definition GCIG Clinical Trials Bibliography CCRN Committee Clinical Q&A Harmonization

Home / Event Listing / Archived Events

Archived Events

Archived Upcoming

Filter by Group
Select...

Items per page 50 Currently viewing events 1 - 5 between 08/25/2015 and 04/28/2016. Viewing page 1 of 1

Event	Start	End	Groups
GOC's 16th Annual CPD Meeting	04/28/2016 12:06 AM EDT	04/30/2016 11:59 PM EDT	
4th Biennial Meeting Of Asian Society of Gynecologic Oncology	11/12/2015 9:00 AM EST	11/14/2015 9:00 AM EST	
2015 GCIG Annual Autumn Meeting	11/10/2015 9:04 AM EST	11/11/2015 9:04 AM EST	
GCIG 5th Ovarian Cancer Consensus Conference	11/07/2015 9:06 AM EST	11/09/2015 9:06 AM EST	
Test Event	08/25/2015 2:44 AM EDT	08/25/2015 3:44 AM EDT	

Archived (past meetings)

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Search

Home Membership **Calendar** Library Harmonization Committee Meetings Announcements

CA 125 Response Definition GCIG Clinical Trials Bibliography CCRN Committee Clinical Q&A Harmonization

Home / Calendar / Event Listing / Upcoming Events

Upcoming Events

Archived Upcoming

Filter by Group
Select...

Items per page 50 Currently viewing events 1 - 4 between 06/02/2016 and 10/27/2016. Viewing page 1 of 1

Event	Start	End	Groups
2016 GCIG Annual Spring Meeting	06/02/2016 8:00 AM EDT	06/03/2016 4:30 PM EDT	
GOC's 37th Annual General Meeting	06/16/2016 12:00 AM EDT	06/18/2016 11:59 PM EDT	
2016 GCIG Annual Autumn Exec Meeting	10/26/2016 3:00 PM EDT	10/26/2016 6:00 PM EDT	
2016 GCIG Annual Autumn Meeting	10/27/2016 8:00 AM EDT	10/28/2016 6:00 PM EDT	

Upcoming

Calendar

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



[Home](#) ▾ [Membership](#) **[Calendar](#)** [Library](#) ▾ [Harmonization Committee](#) [Meetings](#) ▾ [Announcements](#)

[CA 125 Response Definition](#) [GCIG Clinical Trials](#) [Bibliography](#) [CCRN Committee](#) ▾ [Clinical Q&A](#) [Harmonization](#)

[Home](#) / [Calendar of Events](#) / Calendar of Events

Calendar of Events

[Add Event](#)

June 2016

« Prev Next »

Sun	Mon	Tue	Wed	Thu	Fri	Sat
29	30	31	1	2 2016 GCIG Annual Spring Meeting Thu, 06/02/2016 – 08:00	3	4
5	6	7	8	9	10	11
12	13	14	15	16 GOC's 37th Annual	17	18
19	20	21	22	23	24	25
26	27	28	29	30	1	2

Click Event

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



[Home](#) ▾ [Membership](#) [Calendar](#) ▾ [Library](#) ▾ [Harmonization Committee](#) [Meetings](#) ▾ [Announcements](#)

[CA 125 Response Definition](#) [GCIG Clinical Trials](#) [Bibliography](#) [CCRN Committee](#) ▾ [Clinical Q&A](#) [Harmonization](#)

[Home](#) / [Events](#) / 2016 GCIG Annual Spring Meeting

2016 GCIG Annual Spring Meeting

[View](#)[Edit](#)[Add Agenda](#)[Attending](#)[Not Attending](#)[Send Reminder](#)

Start	Thursday, June 2, 2016 - 08:00
End	Friday, June 3, 2016 - 16:30
Type	Face to face
Additional Information	Chicago

Agenda Administration

[Show row weights](#)

Topic		Presenter
Chicago 2016 Agendas		dcc

[Save Changes](#)

Click Agenda

Groups for Clinical Trials in Gynecologic Cancers

Search

Home ▾ Membership Calendar ▾ Library ▾ Harmonization Committee Meetings ▾ Announcements

CA 125 Response Definition GCIG Clinical Trials Bibliography CCRN Committee ▾ Clinical Q&A Harmonization

[Home](#) / [Events](#) / [2016 GCIG Annual Spring Meeting](#) / [Chicago 2016](#)

Agenda *Chicago 2016* has been updated.

Chicago 2016

[View](#)[Edit](#)

Item Number	2 of 2 total
Presenter	dcc
Event	2016 GCIG Annual Spring Meeting (06/02/2016 8:00–4:30 PM EDT)

Description

2016 June final AGENDAs


Attachments:

Attachment	Size
 Overall Schedule - Chicago 2016	98.31 KB
 Sattelite Schedule - Chicago 2016	179.87 KB
 Cervix Committee - Chicago 2016	323.09 KB
 CCRN Committee - Chicago 2016	349.94 KB
 Megadatabase - Chicago 2016	156.12 KB
 Ovary Committee - Chicago 2016	350.15 KB
 Endometrial Committee - Chicago 2016	229.78 KB
 Education WG - Chicago 2016	68.42 KB
 Rare Tumors Committee - Chicago 2016	302.97 KB
 Symptom Benefit Committee - Chicago 2016	249.24 KB
 Translational Science Committee - Chicago 2016	206.14 KB
 Phase 2 Committee - Chicago 2016	107.92 KB
 General Assembly Agenda - Chicago 2016	139.98 KB

See all
agendas
associated
with the
meeting.

Meetings

See past meeting's overall agendas and a preview page for each meeting.



Home ▾ Membership Calendar ▾ Library ▾ Harmonization Committee **Meetings** Announcements

CA 125 Response Definition GCIG Clinical Trials Bibliography CCRN Committee ▾ Clinical Q&A Harmonization

[Home](#) / [Meetings](#)

Meetings

[View](#)[Edit](#)

The Gynecologic Cancer Intergroup (GCIG) supports semiannual meetings, in order to foster growth and promote international cooperation for its members.

[Travel Support Application](#)

GCIG Meeting Schedules

Spring

[Chicago 2016](#)

[Chicago 2015](#)

[Chicago 2014](#)

[Chicago 2013](#)

[Chicago 2012](#)

Fall

[Lisbon 2016](#)

[Tokyo 2015](#)

[Melbourne 2014](#)

[London 2013](#)

[Leiden 2012](#)

Lisbon 2016

[Chicago 2016](#)

[Japan 2015](#)

[Chicago 2015](#)

[Melbourne 2014](#)

[Chicago 2014](#)

[London 2013](#)

[Chicago 2013](#)

Booking Information for GCIG Lisbon 2016

2016 GCIG Annual Autumn Exec Meeting ~10/26/2016

2016 GCIG Annual Autumn Meeting ~10/27/2016 ~10/28/2016

Your web page address is: https://secure3.hilton.com/en_US/dt/reservation/book.htm?execution=e1s1

A block of rooms have been reserved for GCIG Meeting at the DoubleTree by Hilton Lisbon Fontana Park.

This special room rate will be available until 25th of July or until the group block is sold-out, whichever comes first.

[Edit](#) | [View](#)

Click Meeting Date

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers

[Home](#)[Membership](#)[Calendar](#)[Library](#)[Harmonization Committee](#)[Meetings](#)[Announcements](#)[CA 125 Response Definition](#)[GCIG Clinical Trials](#)[Bibliography](#)[CCRN Committee](#)[Clinical Q&A](#)[Harmonization](#)[Home](#) / [Meetings](#) / [Chicago 2016](#)

Chicago 2016

[View](#)[Edit](#)

Gynecologic Cancer Intergroup (GCIG)

GCIG 2016 Spring Meeting

Chicago, IL US

June, 2016

- [Overall Schedule](#)
- [Satellite Schedule](#)

[2016 June Registration Form](#)

[2016 June Invitation Letter](#)

- Cervix Committee
 - [Agenda](#)
- CCRN Committee
 - [Agenda](#)
- Megadatabase
 - [Agenda](#)
- Ovary Committee
 - [Agenda](#)
- Endometrial Committee
 - [Agenda](#)
- Education WG
 - [Agenda](#)
- Rare Tumors Committee
 - [Agenda](#)

See agendas
and slides
associated with
the meeting.

GCIG Clinical Trials

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



Home ▾ Membership Calendar ▾ Library ▾ Harmonization Committee Meetings ▾ Announcements


CA 125 Response Definition **GCIG Clinical Trials** Bibliography CCRN Committee ▾ Clinical Q&A Harmonization

[Home](#) / [GCIG Clinical Trials By Lead Cooperative Group](#)

GCIG Clinical Trials By Lead Cooperative Group

Trial▲	Trial Number	Trial Description	Contact Person	Additional Info	Lead Cooperative Group
55994	ClinicalTrials.gov Identifier: NCT00039338	Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer	Stefano Gregg		EORTC GCG (European Organization for Research and Treatment of Cancer Gynecologic Cancer Group)
AGO - OVAR OP.3 (LION)	ClinicalTrials.gov Identifier: NCT00712218	Lymphadenectomy In Ovarian Neoplasms			AGO-OVAR
AGO-OVAR 2.21	ClinicalTrials.gov Identifier: NCT01837251	A prospective randomized Phase III trial of carboplatin/gemcitabine /bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer			AGO-OVAR

Click Trial



The screenshot shows the homepage of the Gynecologic Cancer Intergroup (GCIG) website. At the top, there is a logo with the text "An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers" and a search bar. Below the logo is a navigation menu with links to Home, Membership, Calendar, Library, Harmonization Committee, Meetings, and Announcements. A secondary menu includes CA 125 Response Definition, GCIG Clinical Trials, Bibliography, GCRN Committee, Clinical Q&A, and Harmonization. The main content area displays the breadcrumb "Home / DESKTOP III (AGO-OVAR OP.4)" and the title "DESKTOP III (AGO-OVAR OP.4)". Below the title are two buttons: "View" and "Edit". The "Trial Description:" section follows, containing a paragraph about the trial, the contact person (Philipp Harter), the lead cooperative group (AGO-OVAR), and a list of participating groups (AGO-AUST, AGO-OVAR, GEICO, NSGO). It also includes the trial number and the ClinicalTrials.gov identifier.

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Search

Home ▾ Membership Calendar ▾ Library ▾ Harmonization Committee Meetings ▾ Announcements

CA 125 Response Definition GCIG Clinical Trials Bibliography GCRN Committee ▾ Clinical Q&A Harmonization

Home / DESKTOP III (AGO-OVAR OP.4)

DESKTOP III (AGO-OVAR OP.4)

[View](#) [Edit](#)

Trial Description:
A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

Contact Person:
[Philipp Harter](#)

Lead Cooperative Group:
[AGO-OVAR](#)

Participating Groups:
[AGO-AUST](#) (Arbeitsgemeinschaft Gynaekologische Onkologie Austria)
[AGO-OVAR](#)
[GEICO](#) (Grupo Espanol de Investigacion en Cancer de Ovario)
[NSGO](#) (Nordic Society of Gynecologic Oncology)

Trial Number:
[ClinicalTrials.gov Identifier: NCT01166787](#)

See trial description, Contact person, lead groups, participating groups, associated trial numbers.

Click Trial Number

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

Example: "Heart attack" AND "Los Angeles"
Search for studies:
[Advanced Search](#) | [Help](#) | [Studies by Topic](#) | [Glossary](#)

[Find Studies](#) ▾ [About Clinical Studies](#) ▾ [Submit Studies](#) ▾ [Resources](#) ▾ [About This Site](#) ▾

[Home](#) > [Find Studies](#) > [Search Results](#) > [Study Record Detail](#)

[Text Size](#) ▾

Trial record **1 of 1** for: DESKTOP III

[Previous Study](#) | [Return to List](#) | [Next Study](#)

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOP III)


This study is ongoing, but not recruiting participants.	ClinicalTrials.gov Identifier: NCT01166737
Sponsor: AGO Study Group	First received: July 16, 2010 Last updated: December 22, 2015 Last verified: December 2015 History of Changes
Collaborators: ARCAGY/ GINECO GROUP MITO Arbeitsgemeinschaft Gynaekologische Onkologie Austria GlaxoSmithKline medac GmbH Grupo Español de Investigación en Cáncer de Ovario NSGO MaNGO Cancer Research UK Korean Gynecologic Oncology Group Shanghai Gynecologic Oncology Group	
Information provided by (Responsible Party): AGO Study Group	
Full Text View	Tabular View
No Study Results Posted	Disclaimer How to Read a Study Record

► Purpose

It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this **third DESKTOP** study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.

Trial number takes you to the associated clinicaltrials.gov page.

Bibliography

[Home](#)[Membership](#)[Calendar](#)[Library](#)[Harmonization Committee](#)[Meetings](#)[Announcements](#)[CA 125 Response Definition](#)[GCIG Clinical Trials](#)[Bibliography](#)[CCRN Committee](#)[Clinical Q&A](#)[Harmonization](#)[Home](#) / [Biblio](#)

Biblio

[Author](#) [Keyword](#) [Title](#) [Type](#) [Year](#) ▼

Found 261 results

2016

S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H., Nam, B. - H., Jhingran, A., Temkin, S., Mileschkin, L., Berns, E., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., "Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.", *Int J Gynecol Cancer*, vol. 26, no. 1, p. 207, 2016.

P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M., del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and Bois, Adu, "BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.", *Gynecol Oncol*, vol. 140, no. 3, pp. 443-9, 2016.

J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M., Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A., Kaplan, R. S., and Parmar, M. K. B., "Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.", *Lancet*, vol. 387, no. 10023, pp. 1066-74, 2016.

A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., "Fertility preservation: A key survivorship issue for young women with cancer ", *Frontiers in Oncology* , vol. 6, no. 102, 2016.

S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A., "Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.", *Gynecol Oncol*, vol. 140, no. 1, p. 94, 2016.

K. Katherine, Julia, B., Valerie, B., Amit, O., and Stephanie, L., "Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ", *Frontiers in Oncology* , vol. 6, no. 00119 , 2016.

L. Brotto, Brundage, M., Hoskins, P., Vergote, I., Cervantes, A., Casado, H. A., Poveda, A., Eisenhauer, E., and Tu, D., "Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.", *Support Care Cancer*, vol. 24, no. 3, p. 1249, 2016.

S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., "Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer", *Frontiers in Oncology* , vol. 6, no. 00118 , 2016.

Adu Bois, Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjerger, L., Lortholary, A., Sailer, M., Oliver, Merger, M., and Harter, P., "Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer

All GCIG group publications.

Sort or Search

Ex. Temkin:

The screenshot shows the Cancer Intergroup website. The header includes the organization's name and a search bar. A navigation menu lists various sections like Home, Membership, Calendar, Library, Harmonization Committee, Meetings, and Announcements. Below the menu, there's a 'Biblio' section with a search bar and filters. The search results show two entries for 'Temkin, Sarah' from 2016, both related to 'Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.' The first entry is by S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H., Nam, B. - H., Jhingran, A., Temkin, S., Mileskin, L., Berns, E., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., published in *Int J Gynecol Cancer*, vol. 26, no. 1, p. 207, 2016. The second entry is by S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., published in *Frontiers in Oncology*, vol. 6, no. 00118, 2016.

The screenshot shows the Cancer Intergroup website. The header includes the organization's name and a search bar. A navigation menu lists various sections like Home, Membership, Calendar, Library, Harmonization Committee, Meetings, and Announcements. Below the menu, there's a 'Search' section with a search bar and filters. The search results show two entries for 'Temkin' from 2016, both related to 'Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.' The first entry is by S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H., Nam, B. - H., Jhingran, A., Temkin, S., Mileskin, L., Berns, E., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., published in *Int J Gynecol Cancer*, vol. 26, no. 1, p. 207, 2016. The second entry is by S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., published in *Frontiers in Oncology*, vol. 6, no. 00118, 2016.

Click Temkin and all the associated articles show.

Search Temkin and anything on the website associated with her appears.

Bibliography Entry Information

[Home](#) / Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC-GCG Gynecologic Cancer InterGroup study.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC-GCG Gynecologic Cancer InterGroup study.

[View](#)[Edit](#)

SUBMITTED BY DCC ON FRI, 10/30/2015 — 16:26

Title	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC-GCG Gynecologic Cancer InterGroup study.
Publication Type	Journal Article
Year of Publication	2014
Authors	Vergote, I, Joly, F, Jimeno, A, Katsaros, D, Coens, C, Despierre, E, Marth, C, Hall, M, Steer, CB, Colombo, N, Lesoin, A, Casado, A, Reinthaller, A, Green, J, Buck, M, Ray-Coquard, I, Ferrero, A, Favier, L, Reed, NS, Curé, H, Pujade-Lauraine, E
Journal	Journal of Clinical Oncology
Volume	1
Issue	32
Start Page	320
Pagination	326
Date Published	02/2014
Keywords	AGO Au, ANZGOG, EORTC-GCG, GINECO, MaNGO

[Google Scholar](#)

Clinical Q & A

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers

Username



Search



Home

Membership

Calendar

Meetings

CA 125 Response Definition

GCIG Clinical Trials

Bibliography

CCRN Committee

Clinical Q&A

Harmonization

[Home](#) / [Clinical Q&A](#)

Clinical Q&A

Recent clinical questions posed to the group by GCIG members. Click the link to see full list of replies.

<u>Topic</u>	<u>Submitted By</u>
Clear Cell Carcinoma of the Cervix	Michael Quinn
Laparoscopic BSO in Turner Syndrome Patient	Philipp Harter
Grade 1 Immature Teratoma	Michael Birrer
UTROSCT (Uterine Tumor Resembling Ovarian Sex Cord Tumor)	Mansoor Raza Mirza
Grade 3 Mucinous Tumor	Michael Quinn
Carcinosarcoma of the Ovary	Amit Oza
Ewing Sarcoma of the ovary	Philipp Harter
Sertoli-Leydig-tumor	Andreas duBois
Adenocarcinoma of the Vulva	Brigitte Miller
Endometriosis with adenocarcinoma	Christian Marth
Alveolar soft tissue sarcoma	Stefano Greggi
Endometrial high-grade stromal sarcoma	David Gaffney
Small cell carcinoma of the cervix	Michael Birrer
Small cell carcinoma of the ovary	David Gaffney
Endocervical adenocarcinoma	Andres Poveda
Recurrent Sertoli-Leydig tumor	Michael Friedlander
Angiosarcoma of the ovary	Ann Oakin

List of questions asked to the group and who asked.

Click Topic

See question and responses from group members.

[Home](#) / [Clear Cell Carcinoma of the Cervix](#)

Basic page *Clear Cell Carcinoma of the Cervix* has been updated.

Clear Cell Carcinoma of the Cervix

[View](#)[Edit](#)

Question:

Dear friends,

16yo. presented with PCB, mass on cervix, consistent with 1B1 (3cm lesion biopsy proven extent of lesion). Biopsy confirms clear cell CA. PET/MRI shows disease confined to cervix.

Neoadjuvant chemo given, carbo/taxol, good 2 cycles response, downsized, then TLRH, conservation of ovaries.

Final path of hyst specimen, shows margins well clear, all nodes -ve. No LVSI. Note final tumor 9mm on path. See all other attached info.

We are grappling with whether to give her any adjuvant. Half of us want to offer her 2 more cycles chemo, whereas some of us feel she is adequately treated. No strong consensus on XRT, as the whole point was to avoid that....

Thanks,

Michael Quinn

Response # 1:

My thoughts - no radiation therapy - but I would give her 2 more courses of chemotherapy since there was still residual disease left in the specimen
Anuja Jhingran

Response # 2:

I would probably give her more chemo either 2 or 3 cycles carbo-pac.
Alternative is single agent cisplatin 4-6 cycles of 50 mg/ms.
I would also think about vag colpostats? Did you do oophoropexy??
Tricky but is saving fertility better than saving life?

Nick

Dr. Nicholas Reed

Roster

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers

[Home](#)[Membership](#)[Calendar](#)[Meetings](#)[CA 125 Response Definition](#)[GCIG Clinical Trials](#)[Bibliography](#)[CCRN Committee](#)[Clinical Q&A](#)[Harmonization](#)

[Home](#) / [Home](#) / [GCIG Roster](#)

GCIG Roster

Welcome to the GCIG Roster page.

Cooperative Group Members

AGO-AUST (Arbeitsgemeinschaft Gynaekologische Onkologie Austria) Address: AGO-Studienzentrale, Med. Univ. Innsbruck, Dept. Gynaecology and Obstetrics, Anichstr. 35, 6020 Innsbruck, Austria E-Mail: ago.studienzentrale@i-med.ac.at Website: www.ago-austria.at [Regina Berger](#) (Harmonization Ops) - Regina.Berger@i-med.ac.at

[Gerhard Bogner](#) - g.bogner@salk.at

[Christian Marth](#) (Director) - Christian.Marth@i-med.ac.at

[Christian Schauer](#) - christian.schauer@bbg Graz.at

[Paul Speiser](#) - paul.speiser@meduniwien.ac.at

[Alain Zeimet](#) - alain.zeimet@uki.at

[Birgit Volgger](#) - b.volgger@onet.at

[Christoph Grimm](#) - christoph.grimm@meduniwien.ac.at

[Nicole Concin](#) - Nicole.Concin@i-med.ac.at

[Lukas Angleitner-Boubenizek](#) - Lukas.angleitner-boubenizek@bhs.at

ECOG-ACRIN (American College of Radiology Imaging Network) Address: American College of Radiology Imaging Network 1818 Market Street, Suite 1720 Philadelphia, PA 19103 Phone: 215-574-3150 or 800-227-5463, extension 4150 Website: <https://www.acrin.org/> [Mostafa Atri](#) - mostafa.atri@rogers.com

[Constantine Gatsonis](#) - gatsonis@stat.brown.edu


[Perry Grigsby](#) - pgrigsby@radonc.wustl.edu

[Susanna I. Lee](#) (Director) - slee0@partners.org

[Chaan Ng](#) (Harmonization Ops) - cng@mdanderson.org

[Russell Schilder](#) - russell.schilder@jefferson.edu

Click Name



Username



Search



[Home](#) ▾ [Membership](#) [Calendar](#) ▾ [Meetings](#) ▾ [CA 125 Response Definition](#) [GCIG Clinical Trials](#) [Bibliography](#)
[CCRN Committee](#) ▾ [Clinical Q&A](#) [Harmonization](#)

[Home](#) / [Alexander Reuss](#)

Alexander Reuss

Email Address:

alexander.reuss@kks.uni-marburg.de

Group:

[AGO \(Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany\)](#)

Title:

Harm Stats Committee Co-Chair


Groups:

[AGO \(Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany\)](#)

Email address, group, and title associated with the Member

Click Group

GCIG Clinical Trials
And Members associated
with this group



Username



Search



Home

Membership

Calendar

Meetings

CA 125 Response Definition

GCIG Clinical Trials

Bibliography

CCRN Committee

Clinical Q&A

Harmonization

[Home](#) / [AGO \(Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany\)](#)

AGO (Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany)

NCIC CTG CX.5/GCIG SHAPE

[Read more](#)

Alexander Reuss

[Read more](#)

Sandra Polleis

[Read more](#)

Jacobus Pfisterer

[Read more](#)

Sven Mahner

[Read more](#)

Link

- ▶ <https://gciggroup.com/>